Skip to main content
Top
Published in: Abdominal Radiology 1/2015

01-01-2015

Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma

Authors: Yuki Makino, Yasuharu Imai, Takumi Igura, Masatoshi Hori, Kazuto Fukuda, Yoshiyuki Sawai, Sachiyo Kogita, Norihiko Fujita, Tetsuo Takehara, Takamichi Murakami

Published in: Abdominal Radiology | Issue 1/2015

Login to get access

Abstract

Purpose

To assess the feasibility of fusion of pre- and post-ablation gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-MRI) to evaluate the effects of radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC), compared with similarly fused CT images

Patients and methods

This retrospective study included 67 patients with 92 HCCs treated with RFA. Fusion images of pre- and post-RFA dynamic CT, and pre- and post-RFA Gd-EOB-DTPA-MRI were created, using a rigid registration method. The minimal ablative margin measured on fusion imaging was categorized into three groups: (1) tumor protruding outside the ablation zone boundary, (2) ablative margin 0–<5.0 mm beyond the tumor boundary, and (3) ablative margin ≥5.0 mm beyond the tumor boundary. The categorization of minimal ablative margins was compared between CT and MR fusion images.

Results

In 57 (62.0%) HCCs, treatment evaluation was possible both on CT and MR fusion images, and the overall agreement between them for the categorization of minimal ablative margin was good (κ coefficient = 0.676, P < 0.01). MR fusion imaging enabled treatment evaluation in a significantly larger number of HCCs than CT fusion imaging (86/92 [93.5%] vs. 62/92 [67.4%], P < 0.05).

Conclusions

Fusion of pre- and post-ablation Gd-EOB-DTPA-MRI is feasible for treatment evaluation after RFA. It may enable accurate treatment evaluation in cases where CT fusion imaging is not helpful.
Literature
2.
go back to reference Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef Bruix J, Sherman M, Llovet JM, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRef
3.
go back to reference Fujioka C, Horiguchi J, Ishifuro M, et al. (2006) A feasibility study: evaluation of radiofrequency ablation therapy to hepatocellular carcinoma using image registration of preoperative and postoperative CT. Acad Radiol 13:986–994PubMedCrossRef Fujioka C, Horiguchi J, Ishifuro M, et al. (2006) A feasibility study: evaluation of radiofrequency ablation therapy to hepatocellular carcinoma using image registration of preoperative and postoperative CT. Acad Radiol 13:986–994PubMedCrossRef
4.
go back to reference Makino Y, Imai Y, Igura T, et al. (2013) Utility of CT fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. Hepatol Res 43:950–958. doi:10.1111/hepr.12049 PubMedCrossRef Makino Y, Imai Y, Igura T, et al. (2013) Utility of CT fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. Hepatol Res 43:950–958. doi:10.​1111/​hepr.​12049 PubMedCrossRef
5.
go back to reference Niculescu G, Foran DJ, Nosher J (2007) Non-rigid registration of the liver in consecutive CT studies for assessment of tumor response to radiofrequency ablation. Conf Proc IEEE Eng Med Biol Soc 2007:856–859 Niculescu G, Foran DJ, Nosher J (2007) Non-rigid registration of the liver in consecutive CT studies for assessment of tumor response to radiofrequency ablation. Conf Proc IEEE Eng Med Biol Soc 2007:856–859
6.
go back to reference Giesel FL, Mehndiratta A, Locklin J, et al. (2009) Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol 31:106–114PubMedCentralPubMed Giesel FL, Mehndiratta A, Locklin J, et al. (2009) Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol 31:106–114PubMedCentralPubMed
7.
go back to reference Kim YS, Lee WJ, Rhim H, et al. (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195:758–765. doi:10.2214/AJR.09.2954 PubMedCrossRef Kim YS, Lee WJ, Rhim H, et al. (2010) The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (>2 and <5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol 195:758–765. doi:10.​2214/​AJR.​09.​2954 PubMedCrossRef
8.
go back to reference Kim KW, Lee JM, Klotz E, et al. (2011) Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol 196:W565–W572. doi:10.2214/AJR.10.5122 PubMedCrossRef Kim KW, Lee JM, Klotz E, et al. (2011) Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR Am J Roentgenol 196:W565–W572. doi:10.​2214/​AJR.​10.​5122 PubMedCrossRef
9.
go back to reference Tomonari A, Tsuji K, Yamazaki H, et al. (2013) Feasibility of fused imaging for the evaluation of radiofrequency ablative margin for hepatocellular carcinoma. Hepatol Res 43:728–734. doi:10.1111/hepr.12022 PubMedCrossRef Tomonari A, Tsuji K, Yamazaki H, et al. (2013) Feasibility of fused imaging for the evaluation of radiofrequency ablative margin for hepatocellular carcinoma. Hepatol Res 43:728–734. doi:10.​1111/​hepr.​12022 PubMedCrossRef
11.
go back to reference Murakami T, Imai Y, Okada M, et al. (2011) Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 81(Suppl 1):86–99. doi:10.1159/000333267 PubMedCrossRef Murakami T, Imai Y, Okada M, et al. (2011) Ultrasonography, computed tomography and magnetic resonance imaging of hepatocellular carcinoma: toward improved treatment decisions. Oncology 81(Suppl 1):86–99. doi:10.​1159/​000333267 PubMedCrossRef
12.
15.
go back to reference Okada M, Imai Y, Kim T, et al. (2010) Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 32:903–913. doi:10.1002/jmri.22333 PubMedCrossRef Okada M, Imai Y, Kim T, et al. (2010) Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 32:903–913. doi:10.​1002/​jmri.​22333 PubMedCrossRef
16.
go back to reference Di Martino M, Marin D, Guerrisi A, et al. (2010) Intraindividual comparison of gadoxetate disodium-enhanced MRI and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816. doi:10.1148/radiol.10091334 PubMedCrossRef Di Martino M, Marin D, Guerrisi A, et al. (2010) Intraindividual comparison of gadoxetate disodium-enhanced MRI and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816. doi:10.​1148/​radiol.​10091334 PubMedCrossRef
17.
go back to reference Makino Y, Imai Y, Ohama H, et al. (2013) Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. Oncology 84(Suppl 1):44–50. doi:10.1159/000345889 PubMedCrossRef Makino Y, Imai Y, Ohama H, et al. (2013) Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. Oncology 84(Suppl 1):44–50. doi:10.​1159/​000345889 PubMedCrossRef
18.
go back to reference Peng ZW, Zhang YJ, Liang HH, et al. (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700. doi:10.1148/radiol.11110637 PubMedCrossRef Peng ZW, Zhang YJ, Liang HH, et al. (2012) Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology 262:689–700. doi:10.​1148/​radiol.​11110637 PubMedCrossRef
19.
go back to reference Peng ZW, Zhang YJ, Chen MS, et al. (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432. doi:10.1200/JCO.2012.42.9936 PubMedCrossRef Peng ZW, Zhang YJ, Chen MS, et al. (2013) Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 31:426–432. doi:10.​1200/​JCO.​2012.​42.​9936 PubMedCrossRef
22.
go back to reference Nakazawa T, Kokubu S, Shibuya A, et al. (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 188:480–488PubMedCrossRef Nakazawa T, Kokubu S, Shibuya A, et al. (2007) Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 188:480–488PubMedCrossRef
26.
go back to reference Carrillo A, Duerk JL, Lewin JS, Wilson DL (2000) Semiautomatic 3-D image registration as applied to interventional MRI liver cancer treatment. IEEE Trans Med Imaging 19:175–185PubMedCrossRef Carrillo A, Duerk JL, Lewin JS, Wilson DL (2000) Semiautomatic 3-D image registration as applied to interventional MRI liver cancer treatment. IEEE Trans Med Imaging 19:175–185PubMedCrossRef
27.
go back to reference Dromain C, de Baere T, Elias D, et al. (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MRI follow-up. Radiology 223:255–262PubMedCrossRef Dromain C, de Baere T, Elias D, et al. (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MRI follow-up. Radiology 223:255–262PubMedCrossRef
28.
go back to reference Bangard C, Stippel DL, Berg F, et al. (2008) Conspicuity of zones of ablation after radiofrequency ablation in porcine livers: comparison of an extracellular and an SPIO contrast agent. J Magn Reson Imaging 28:263–270. doi:10.1002/jmri.21423 PubMedCrossRef Bangard C, Stippel DL, Berg F, et al. (2008) Conspicuity of zones of ablation after radiofrequency ablation in porcine livers: comparison of an extracellular and an SPIO contrast agent. J Magn Reson Imaging 28:263–270. doi:10.​1002/​jmri.​21423 PubMedCrossRef
29.
go back to reference Yoon JH, Lee EJ, Cha SS, et al. (2010) Comparison of gadoxetic acid-enhanced MRI versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 21:348–356. doi:10.1016/j.jvir.2009.11.014 PubMedCrossRef Yoon JH, Lee EJ, Cha SS, et al. (2010) Comparison of gadoxetic acid-enhanced MRI versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 21:348–356. doi:10.​1016/​j.​jvir.​2009.​11.​014 PubMedCrossRef
30.
go back to reference Crum WR, Hartkens T, Hill DL (2004) Non-rigid image registration: theory and practice. Br J Radiol 77(Spec No 2):S140–53 Crum WR, Hartkens T, Hill DL (2004) Non-rigid image registration: theory and practice. Br J Radiol 77(Spec No 2):S140–53
31.
go back to reference Kim S, Mannelli L, Hajdu CH, et al. (2006) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355. doi:10.1002/jmri.22038 CrossRef Kim S, Mannelli L, Hajdu CH, et al. (2006) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31:348–355. doi:10.​1002/​jmri.​22038 CrossRef
32.
go back to reference Khankan AA, Murakami T, Onishi H, et al. (2008) Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 27:546–551. doi:10.1002/jmri.21050 PubMedCrossRef Khankan AA, Murakami T, Onishi H, et al. (2008) Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 27:546–551. doi:10.​1002/​jmri.​21050 PubMedCrossRef
33.
go back to reference Koda M, Tokunaga S, Fujise Y, et al. (2012) Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol 81:1400–1404. doi:10.1016/j.ejrad.2011.03.004 PubMedCrossRef Koda M, Tokunaga S, Fujise Y, et al. (2012) Assessment of ablative margin after radiofrequency ablation for hepatocellular carcinoma; comparison between magnetic resonance imaging with ferucarbotran and enhanced CT with iodized oil deposition. Eur J Radiol 81:1400–1404. doi:10.​1016/​j.​ejrad.​2011.​03.​004 PubMedCrossRef
Metadata
Title
Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma
Authors
Yuki Makino
Yasuharu Imai
Takumi Igura
Masatoshi Hori
Kazuto Fukuda
Yoshiyuki Sawai
Sachiyo Kogita
Norihiko Fujita
Tetsuo Takehara
Takamichi Murakami
Publication date
01-01-2015
Publisher
Springer US
Published in
Abdominal Radiology / Issue 1/2015
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-014-0201-2

Other articles of this Issue 1/2015

Abdominal Radiology 1/2015 Go to the issue

Classics in Abdominal Imaging

The hamburger sign (sandwich sign)

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine